ここから本文です

投稿コメント一覧 (2367コメント)

  • ※25th Protein Structure Determination in Industry Meeting: 12-14 November 2017, Cambridge, UK. (9/24 update)
    ・13 Nov - Scientific Meeting - Drug Design Case Studies, 10:25, Andrew S Dore (Heptares Therapeutics Ltd)
    ・14 Nov - Scientific Meeting - Membrane Proteins & Hot Structures, 12:05, Chris Tate (MRC LMB)
    ※Global Medicinal Chemistry & GPCR Leaders Summit, 27-28 November 2017, London, UK
    ・28 Nov, 8:40, "Structure Based Drug Design Applied to Allosteric Modulators of GPCRs": Fiona Marshall (Expert Speaker).
    ・28 Nov, 14:45, "High End GPCR SBDD: The Revolution in GPCR Ligand Design from Multiple Co-Crystal X-Ray Structures": Jonathan Mason.
    ・・・
    Result Events:
    ※Novartis Q3 2017 Earnings Conference Call: (10/24)
    ※大日本住友製薬 2018年3月期第2四半期決算発表: (10/30)
    ※Pfizer Quarterly Corporate Performance Q3 2017: (10/31)
    ※Allergan Q3 2017 Earnings Conference Call: (11/1) 10/2up
    ※Teva Q3 2017 Earnings Conference Call: (11/2)
    ※MorphoSys Publication of Q3 Interim Statement 2017: (11/7)
    ※明治ホールディングス 平成30年3月期 第2四半期決算発表: (11/8)
    ※AstraZeneca Year-to-date and Q3 2017 Results: (11/9)
    ※あすか製薬 平成30年3月期第2四半期決算発表: (11月上旬)
    ※ペプチドリーム 平成30年6月期第1四半期決算発表: (11月上旬)
    ※SOSEI 平成30年3月期第2四半期決算発表: (11月中旬)
    ・・・
    ※SOSEIの成長相場の動向:
    ・Bloomberg:創薬ベンチャーのそーせいは買収を通じて業容を拡大し、株価は過去2年間で約300%上昇(2015/3/17終値2972→2017/3/17終値10750)。
    2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22※最安値1854、2014/9/8最高値6000: PfizerUK)※[成長回収期の入口]ステージへ
    2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章]ステージへ
    2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24※安値3550) (2015/10/29※終値3885:Utibron・Seebri米国承認)※[次なる飛躍]ステージへ
    2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(201511/30終値6060:Pfizer、12/1安値7060)※[上抜け圏]へ・(4/6終値14180:Allergan)※[強気相場]
    2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/5/9最高値26180、6/24安値12960)※[強気相場解除]※[時間軸での調整局面]へ
    2016/12/30 (終値13450) 売残高__300 買残高 2920000 ・(2016/12/8安値12470、1/24安値12910、2/13安値12400)※[時間軸調整は順調に推移]
    2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380) ※[仕掛け、振るい場・拾い場]へ
    2017/_6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960)※[調整終盤での動意待ち]
    2017/_8/25 (終値_9020) 売残高_6400 買残高 2018100(+154400) ・(7/31安値11280、8/10安値10280、8/24安値8860)
    2017/_9/_1 (終値_9710) 売残高_2400 買残高 2048100(_+30000) ・(8/29安値8860)
    2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800(_-10300) ・(9/6※最安値8590)
    2017/_9/15 (終値_8850) 売残高____0 買残高 2002400(_-35400) ・(9/11安値8630)
    2017/_9/22 (終値_9200) 売残高__100 買残高 2021100(_+18700) ・(9/19,20安値8820)
    2017/_9/29 (終値_9500) 売残高_1000 買残高 1961700(_-59400)※10/3up ・(9/26安値8960)※[振るい・拾い場も順調に推移]
    2017/10/_2 (終値_9400) 5日線乖離(+2.02%) 25日線乖離(+3.99%) 75日乖離(-10.91%) 200日線乖離(-18.96%) (安値9360)
    2017/10/_3 (終値_9310) 5日線乖離(+0.28%) 25日線乖離(+2.91%) 75日乖離(-11.54%) 200日線乖離(-19.59%) (安値9260)
    2017/10/_4 (終値_9120) 5日線乖離(-1.81%) 25日線乖離(+0.70%) 75日乖離(-13.12%) 200日線乖離(-21.07%) (安値9090)
    2017/10/_5 (終値_9300) 5日線乖離(-0.28%) 25日線乖離(+2.26%) 75日乖離(-11.18%) 200日線乖離(-19.36%) (安値9270)

    上抜け圏にて、強気相場解除後の時間軸調整は順調に推移。笑。
    ※SOSEI Technical Analysis Charts:
    ・(ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=DAY1&Duration=60&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us)
    ・(ttp://www.4-traders.com/SOSEI-GROUP-CORPORATION-6814799/charts/&applet_mode=statique)
    時間軸調整の終盤、今回も予定通りに推移してますね。笑。

    更なる成長の黎明期にて、R&D等の拡充・進捗や中長期成長戦略も着実に進み、
    次なる展開・進捗が楽しみですね。笑。

  • 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
    成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
    Heptares has been operating for ten years and has over 115 employees in the UK and 6 employees in Zurich.
    The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
    Heptares, will be relocating to the Cambridge area in "July 2018". (9/6up)
    ・・・
    ※大日本住友製薬第1四半期決算説明会:北米COPD新製品群、本年10月に発売予定のシーブリもあわせ、売上拡大に注力。(7/28up)
    ※Pluristem: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018." (Change, 9/17up)
    ※ClinicalTrials.gov: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9." (9/18up)
    ※MRC LMB: Brochure "Impact: Heptares." (9/19update) ※LMB PhD Programme: " Chris Tate: Cryo-EM of GPCRs." Applications now open. (9/22)
    ※MiNA: MiNA Research Team at OTS2017. "MTL-CEBPA, encouraging early clinical data in a Phase 1 trial in HCC."(9/22)
    ※日本特許:ムスカリンM1受容体作動薬としての二環式アザ化合物 (9/27公開)
    ※Protein Data Bank: "A2A Adenosine Receptor Cryo Structure and Room-Temperature Structure" (LeadXpro and Heptares):5NLX, 5NM2, 5NM4. (9/27 Released)
    ※Heptares Corporate Overview 2017. (9/27update) ※Heptares_HP_Pipeline: Muscarinic M1 Status. (9/28Change)
    ・HTL009936/HTL0018318: first-in-class oral agents in Phase 1 clinical studies. "Planning underway for studies in AD patients"
    ・Wave 1 Partnered Pipeline: M1, Progression 2017-2019: "Start of Phase 2 POC trial in AD patients", "AD PoC results emerging"
    ・Wave 2 Proprietary Pipeline: "Multiple Candidates Entering Clinic from H2 2017", "mGlu5: 2017 Phase 1 SAD/MAD and PET receptor occupancy"
    ※米国特許出願:4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGlu5 Modulators. (9/28公開)
    ※mGlu International Meeting: "Structure Based Drug Design Applied to the mGlu5 Receptor." Fiona Marshall. (10/2)
    ※Drug Discovery 2017: "Deciphering GPCR-ligand interactions through structural and biophysical investigations." Rob Cooke. (10/3)
    ・Heptares Rob Cooke walks us through unexpected binding sites in GPCR. The Merck MK-0893 Story a GCGR Antagonist.
    ・Some targets w/ no druggable sites at all, others with multiple ones: PAR2 + its Astrazeneca AZ8838 Antagonist. Heptares

    ※MRC LMB: Huge congratulations to Richard Henderson. Wins 2017 Nobel Prize for Chemistry. (10/4)
    ・Fiona Marshall: So delighted that Heptares founder Richard Henderson has won the Nobel Prize. "Uses of Cryo-EM Just Beginning." (10/4)
    ・Heptares TL: We're delighted to hear that Heptares co-founder Richard Henderson is a recipient of this year's Nobel Prize in Chemistry. (10/4)
    ※Heptares: Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for Pioneering Work in Cryo-EM for Visualising Biological Structures. (10/5)
    ※SOSEI:Heptares創設者Richard Hendersonが、生物学的構造を画像として解析することのできるクライオ電子顕微鏡(CRYO-EM)の開発により、2017年ノーベル化学賞を受賞。(10/5)
    ・膜たんぱく質構造に関する彼の偉業は、Heptares社のGPCR構造ベースドラッグデザインにおいて刺激と科学的な基盤をもたらしました。
    ・Heptares社はクライオ電子顕微鏡の技術をGたんぱく質共益受容体(GPCR)複合体に応用し、得られた知見を新規候補薬研究の促進に役立てています。

    ・・・
    ※MiNA: seeking a Senior Research Scientist to join its research team developing novel therapeutics. (10/14 Close)
    ※MiNA: seeking a Research Technician/Laboratory Manager to join its research team developing novel therapeutics. (10/15 Close)
    ※Heptares: seeking an molecular biologist to join the protein engineering group at our site in Zurich working. (10/15 Recruiting End)
    ・・・
    ※23rd Annual Pharmaceutical Pricing and Market Access: 11-12 October 2017, London, UK.
    ・Attending: Heptares Therapeutics.
    ※K4DD Scientific Meeting: 16-18 October 2017, Berlin, Germany.
    ・17 Oct, 17:30, "Building a complete picture: kinetics, thermodynamics and structural determination of stabilised G protein-coupled receptors" Elena Segala.

  • ※Labiotech.eu: British Biotech Founder Receives the Nobel Prize in Chemistry 2017.
    2017/10/05

    Richard Henderson, awarded the Nobel Prize in Chemistry 2017,
    founded Heptares Therapeutics to apply his Nobel-winning technology to discover new medicines.

    This year’s Nobel Prize in Chemistry has been awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy.
    This technology, now widely used in structural biology labs, is considered a stepping stone in the visualization of life at the molecular level.
    By freezing biomolecules in the middle of their activity, scientists can better understand the inner workings of the molecular machinery that keeps us alive.

    Richard Henderson, working at Cambridge University, was the first to apply electron microscopy to proteins back in 1990, which proved the technology’s potential for biological applications.
    Once the technology was fully developed, in 2007, he co-founded Heptares Therapeutics,
    a biotech company that employs cryo-electron microscopy and other structural visualization techniques to study protein complexes and unveil new drug targets.

    In particular, Heptares Therapeutics focuses on determining the structure of G protein-coupled receptors (GPCRs),
    a protein superfamily that is the target of about 40% of all the world’s drugs, treating everything from diabetes to cancer.
    However, these proteins are exceptionally hard to study and target because they have a very unstable structure.

    Heptares’ StaR technology can stabilize these dodgy molecules to study their structure using cryo-electron microscopy and X-ray crystallography.
    Its huge potential for drug discovery made the British biotech land a €3Bn deal with Allergan last year to develop drugs for Alzheimer’s and other neurological diseases.
    Read more about it in our interview with Heptares’ co-founder Fiona Marshall. ("Pinning Down Elusive Targets": Fiona, interview 2017/7/26)

  • ※Nobel Prize for Cambridge biomolecule pioneer.
    5 October, 2017

    Richard Henderson from the MRC Laboratory of Molecular Biology’ Structural Studies Division and co-founder of Heptares has been awarded the 2017 Nobel Prize for Chemistry.

    He shares the honour jointly with Jacques Dubochet and Joachim Frank
    “for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution.”

    The work of LMB scientists has previously been recognised by the award of 10 Nobel prizes.

    Henderson said:
    “I am delighted for everybody in the field that the Nobel Prize for Chemistry has been awarded to acknowledge the success of cryo-EM.
    “I am particularly pleased that Jacques Dubochet has been recognised as the key person who kick-started the field in the early 1980s
    with his method of rapid freezing to make a specimen of amorphous ice, a crucial advance.”

    Henderson was born and educated in Scotland.
    Following a PhD in Cambridge he worked at Yale University before returning to the LMB
    where he has been working since 1973 on using electron microscopy to solve complex membrane protein structures.

    Together with Nigel Unwin he successfully determined the first structure of 2-D crystals of the membrane protein bacteriorhodopsin using electron microscopy in 1975.

    Work over Richard’s career has helped to advance the technique of electron microscopy,
    which bombards proteins or other large biological molecules with electrons rather than X-rays, so that the atomic structure of proteins can be determined.

    This has allowed us to see the structure of large, flexible and complex proteins, which have been impossible to analyse by traditional X-ray crystallography techniques.

    In the 1990s, Richard realised that it would be theoretically possible to extract enough signal from randomly dispersed molecules using electron microscopy to obtain their detailed atomic structures.

    This insight and Richard’s drive and determination over the next two decades led to the development of better detectors for electron microscopes and better software to analyse the images.

    This revolutionised the technique of electron cryomicroscopy (cryoEM),
    which involves flash-cooling molecules in a thin layer of aqueous solution before imaging them, a crucial method invented by Jacques Dubochet and his colleagues in the early 1980s.
    Computational processing the images is a key step, to which Joachim Frank made major early contributions.

    In the last few years there has been a quantum step forward in these imaging techniques, due to better microscopes,
    better electron detectors and better computer programs for calculating the structure from the images.
    These improvements are now allowing atomic structure determinations of many protein and other macromolecular assemblies that were previously very difficult or impossible to obtain.

    The new structures provide important insights into the biological function of the assemblies and,
    by catalysing the subsequent development of new diagnostic or therapeutic tools, should help to improve the health and wealth of the country.

    executive director at Cambridge University Healkh Partners, said:
    “It is fantastic news to hear we have yet another Nobel prize winner in Cambridge and
    I would like to send my congratulations to Richard Henderson and to the MRC’s Laboratory of Molecular Biology.

    “Richard’s work with his colleagues has had a huge impact on our ability to image biological structures
    and will undoubtedly lead to the development of new and improved ways of diagnosing and treating disease.

    “We should all be very proud that people like Richard base themselves in Cambridge to work and develop their ideas for the benefit of us all.
    The award is also recognition of the cutting edge and innovative work that is taking place on the Cambridge Biomedical Campus every day,
    demonstrating the power and collaboration which has helped the city become the UK’s Capital of Life Sciences.”

  • ※Algorithm designer among those honored with the Chemistry Nobel.
    They took an electron microscope and remade it to take images of single molecules.
    2017/10/06

    The highest possible resolution we can get in a typical image is limited by the wavelength of the light we're using.
    Although there are some clever ways around this limit, one alternative has been to use something with a smaller wavelength.
    That "something" turns out to be electrons, and the electron microscope has provided a glimpse of the details inside cells, showing us how their parts are ordered and structured.

    But this year's Nobel Prize in Chemistry went to a group of individuals who pushed the electron microscope to its very limit,
    figuring out how to use it to determine the position of every single atom in large, complex molecules.
    The award goes partly to a researcher who successfully used electron microscopes to image proteins.
    But it also goes to two people who developed some of the techniques to make the whole thing work:
    figuring out how to freeze water quickly enough that it formed a glass and developing an algorithm that could take a large collection of random data and convert it into a coherent picture.

    Imaging molecules:

    For years, understanding the structure of a complex molecule like a protein or RNA involved a technique called X-ray crystallography.
    As its name implies, this works by shooting X-rays through crystals of the molecule in question.
    But there's a pretty major limitation to this technique: your molecule has to form a crystal. Not all proteins do.
    In fact, some rather important classes of proteins completely refuse to do so, like the ones that are embedded in a cell's membrane.

    But X-rays aren't the only things that bounce off the atoms in a molecule; electrons will as well.
    And if you can image the patterns the electrons form after they bounce off, you can infer where the atoms are.
    An electron microscope is nothing more than a system for focusing beams of electrons and recording where they end up.
    So it should, in principle, work to get you information on where all the atoms are, which tells you the structure of the molecule.

    But the gap between principle and reality here is a canyon-sized chasm.
    To begin with, electrons tend to transfer energy to atoms they bump into, which will break chemical bonds and destroy the molecule.
    So you want as few electrons as possible to do the imaging.
    Yet most of the electrons will pass by a molecule without interacting with it, meaning the actual signal is tiny.
    To bring it up, you need a lot of electrons (which will, of course, damage it).

    Electron microscopy is done in a vacuum.
    But lots of proteins have water molecules tightly linked to them, essentially acting as part of the structure.
    Put them in a vacuum, and the water goes away, taking the structure with it.
    You can freeze the water so it stays in place in a vacuum, but then the ice crystals also interact with the electron, creating a huge signal that swamps your protein.

    Then there's the issue of orientation.
    Without a crystal, each individual protein molecule you try to image will be oriented in a different direction.
    Since you don't know which way any two molecules are pointing, you can't combine the data from both of them to enhance the signal.

    You might think that this would be enough to convince anyone that the use of electron microscopy for figuring out protein structures was an impossibility.
    But scientists can be an extremely stubborn bunch.

    Very different contributions:

    Richard Henderson is cited for his early work in the field.
    ・・・
    Better microscope hardware, especially improved electron detectors, were critical to continuing to refine the techniques.
    But today, cryo electron microscopy has progressed to the point where it's possible to get atomic-resolution images of proteins,
    telling us precisely how their constituent parts combine to create their structure and function - no crystals needed.

  • ※Nobel Prize winner co-founded Cambridge biotech firm Praise for scientist's 'inspirational' work
    October 5, 2017

    A life sciences firm is celebrating after one of its co-founders picked up a Nobel Prize.

    As reported in the News yesterday, Richard Henderson, who works at the MRC molecular biology laboratory in Cambridge, has been awarded the Nobel Prize for Chemistry for his work "developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution.
    " He was given the prize along with fellow scientists Jacques Dubochet (University of Lausanne, Switzerland) and Joachim Frank (Columbia University, New York, USA).

    But back in 2007 he founded Heptares, a life sciences firm developing drugs to target G protein-coupled receptors (GPCRs), which are linked to a range of diseases.
    The company was set up to build on work from the MRC laboratory, as well as the National Institute for Medical Research in London, and Henderson co-founded the business alongside Malcolm Weir, Fiona Marshall and Chris Tate.

    Malcolm Weir, who is new Heptares CEO, said:
    “We are delighted that Richard has received this most prestigious of awards.
    It is very well deserved and justified recognition of his outstanding contribution to science as a true pioneer of structural biology.

    "His work on membrane protein structure in particular provided the inspiration and scientific foundation for Heptares’ work on GPCR structure-based drug design, and we continue to benefit enormously from his contributions.
    We would like to offer Richard and his fellow prize winners our warmest congratulations for this fantastic achievement.”

    Cryo-electron microscopy (cryo-EM) is a technique for determining three-dimensional information about protein structures at the molecular level.
    Along with traditional methods for structure determination, such as x-ray crystallography and nuclear magnetic resonance spectroscopy, cryo-EM can reveal the structure of complex molecular assemblies to near atomic level.

    Detailed information, such as this, is expected to improve understanding of the structure and function of proteins under investigation, and thereby advance the design of new drugs targeting specific proteins.
    Heptares is applying the techniques of cryo-EM to study G protein-coupled receptor (GPCR) protein complexes, the insights from which are helping to advance the discovery of potential new medicines.

    Heptares was purchased by Japanese corporation Sosei in 2015 for $400m.

  • ※Heptares founder Henderson named joint Nobel chemistry prize winner
    October 5, 2017

    Richard Henderson, an influential figure in UK biotech research, has won the Nobel Prize for Chemistry for his work allowing scientists to see the three-dimensional structure of proteins for the first time.

    Henderson, who works for the MRC Laboratory of Molecular Biology (LMB) in Cambridge, was awarded the prize together with Jacques Dubochet,
    from the University of Lausanne in Switzerland, and Joachim Frank of Columbia University in New York.

    The trio were awarded the prize for “developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution”.

    As well as his work at MRC, Henderson was co-founder of the UK biotech Heptares in 2007, along with its current CEO Malcolm Weir, and Fiona Marshall and Chris Tate.

    Heptares’ work focuses on medicines targeting G protein-coupled receptors, a superfamily of 375 receptors linked to a wide range of human diseases.

    Born and educated in Scotland, Henderson got a PhD at Cambridge University before working at Yale University.

    He then returned to the LMB where he has been working since 1973 on using electron microscopy to solve complex membrane protein structures.

    After pioneering work with electron microscopes in the 1970s,
    Henderson realised that it would be possible to extract enough signal from randomly dispersed molecules using electron microscopy to obtain their detailed atomic structures.

    This led to better detectors for electron microscopes, and the crucial work of Dubochet, who devised a way to flash-cool molecules in a thin layer of aqueous solution before imaging them.

    Processing the images with a computer is a key step, to which Joachim Frank made major early contributions.

    The progress in protein imagery has allowed valuable insights into their biological function, catalysing development of diagnostic and therapeutic tools.

    Henderson has recently been awarded the Gjonnes Medal in electron crystallography by the International Union of Crystallography,
    is a Fellow of the Royal Society and the Academy of Medical Sciences, and was director of the LMB from 1996-2006.

  • 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
    成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
    ・・・
    ※大日本住友製薬第1四半期決算説明会:北米COPD新製品群、本年10月に発売予定のシーブリもあわせ、売上拡大に注力。(7/28up)
    ※Pluristem: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018." (Change, 9/17up)
    ※ClinicalTrials.gov: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9." (9/18up)
    ※MRC LMB: Brochure "Impact: Heptares." (9/19update) ※LMB PhD Programme: "Cryo-EM of GPCRs." Applications now open. (9/22)
    ※MiNA: MiNA Research Team at OTS2017. "MTL-CEBPA, encouraging early clinical data in a Phase 1 trial in HCC."(9/22)
    ※日本特許:ムスカリンM1受容体作動薬としての二環式アザ化合物 (9/27公開)
    ※Protein Data Bank: A2A Adenosine Receptor Structure (LeadXpro and Heptares):5NLX, 5NM2. (9/27 Released)
    ※Heptares Corporate Overview 2017. (9/27update) ※Heptares_HP_Pipeline: Muscarinic M1 Status. (9/28Change)
    ・HTL009936/HTL0018318: first-in-class oral agents in Phase 1 clinical studies. "Planning underway for studies in AD patients"
    ・Wave 1 Partnered Pipeline: M1, Progression 2017-2019: "Start of Phase 2 POC trial in AD patients", "AD PoC results emerging"
    ・Wave 2 Proprietary Pipeline: "Multiple Candidates Entering Clinic from H2 2017", "mGlu5: 2017 Phase 1 SAD/MAD and PET receptor occupancy"
    ※米国特許出願:4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGlu5 Modulators. (9/28公開)
    ※mGlu International Meeting: "Structure Based Drug Design Applied to the mGlu5 Receptor." Fiona Marshall. (10/2)
    ※Fiona Marshall: So delighted that Heptares founder Richard Henderson has won the Nobel Prize. "Uses of Cryo-EM Just Beginning." (10/4)
    ※Heptares: We're delighted to hear that Heptares co-founder Richard Henderson is a recipient of this year's Nobel Prize in Chemistry.(10/4)
    ※MRC LMB: Huge congratulations to Richard Henderson. Wins 2017 Nobel Prize for Chemistry. (10/4)
    ・・・
    ※Novartis Q3 2017 Earnings Conference Call: (10/24)
    ※大日本住友製薬 2018年3月期第2四半期決算発表: (10/30)
    ※Pfizer Quarterly Corporate Performance Q3 2017: (10/31)
    ※Allergan Q3 2017 Earnings Conference Call: (11/1) 10/2up
    ※Teva Q3 2017 Earnings Conference Call: (11/2)
    ・・・
    ※SOSEIの成長相場の動向:
    _3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380) ※[仕掛け、振るい場・拾い場]へ
    _6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960)※[調整終盤での動意待ち]
    _8/25 (終値_9020) 売残高_6400 買残高 2018100(+154400) ・(7/31安値11280、8/10安値10280、8/24安値8860)
    _9/_1 (終値_9710) 売残高_2400 買残高 2048100(_+30000) ・(8/29安値8860)
    _9/_8 (終値_8700) 売残高_1900 買残高 2037800(_-10300) ・(9/6※最安値8590)
    _9/15 (終値_8850) 売残高____0 買残高 2002400(_-35400) ・(9/11安値8630)
    _9/22 (終値_9200) 売残高__100 買残高 2021100(_+18700) ・(9/19,20安値8820)
    _9/29 (終値_9500) 売残高_1000 買残高 1961700(_-59400)※10/3up ・(9/26安値8960)※[振るい・拾い場も順調]
    10/_2 (終値_9400) 5日線乖離(+2.02%) 25日線乖離(+3.99%) 75日乖離(-10.91%) 200日線乖離(-18.96%) (安値9360)
    10/_3 (終値_9310) 5日線乖離(+0.28%) 25日線乖離(+2.91%) 75日乖離(-11.54%) 200日線乖離(-19.59%) (安値9260)
    10/_4 (終値_9120) 5日線乖離(-1.81%) 25日線乖離(+0.70%) 75日乖離(-13.12%) 200日線乖離(-21.07%) (安値9090)
    10/_5 (終値_9300) 5日線乖離(-0.28%) 25日線乖離(+2.26%) 75日乖離(-11.18%) 200日線乖離(-19.36%) (安値9270)

    上抜け圏にて、強気相場解除後の時間軸調整は順調に推移。笑。
    ※SOSEI Technical Analysis Charts:
    (ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=120&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us)

    時間軸調整の終盤、今回も予定通りに推移してますね。笑。

    次なる展開・進捗が楽しみですね。笑。

  • ※Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for Pioneering Work in Cryo-EM for Visualising Biological Structures.

    LONDON and TOKYO, October 5, 2017 /PRNewswire/ --

    Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), is delighted that one of its founders, Richard Henderson (MRC Laboratory of Molecular Biology, Cambridge, UK), was awarded the Nobel Prize in Chemistry 2017 together with Jacques Dubochet (University of Lausanne, Switzerland) and Joachim Frank (Columbia University, New York, USA) "for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution."

    Cryo-electron microscopy (cryo-EM) is a technique for determining three-dimensional information about protein structures at the molecular level. Along with traditional methods for structure determination, such as x-ray crystallography and nuclear magnetic resonance spectroscopy, cryo-EM can reveal the structure of complex molecular assemblies to near atomic level. Detailed information, such as this, is expected to improve understanding of the structure and function of proteins under investigation, and thereby advance the design of new drugs targeting specific proteins. Heptares is applying the techniques of cryo-EM to study G protein-coupled receptor (GPCR) protein complexes, the insights from which are helping to advance the discovery of potential new medicines.

    Malcolm Weir, CEO and co-founder Heptares, said: "We are delighted that Richard has received this most prestigious of awards. It is very well deserved and justified recognition of his outstanding contribution to science as a true pioneer of structural biology. His work on membrane protein structure in particular provided the inspiration and scientific foundation for Heptares' work on GPCR structure-based drug design, and we continue to benefit enormously from his contributions. We would like to offer Richard and his fellow prize winners our warmest congratulations for this fantastic achievement."

    Richard Henderson co-founded Heptares Therapeutics with Malcolm Weir, Fiona Marshall and Chris Tate in 2007.

    A link to the press release from the Royal Swedish Academy of Sciences can be found by clicking here.

    About Heptares Therapeutics

    Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares' proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, MorphoSys, Peptidream, Pfizer and Teva.

    Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit www.heptares.com and www.sosei.com.

    HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

    StaR® is a registered trademark in the EU and Japan.

    About Sosei

    Sosei is a biopharmaceutical company originating from Japan but with global presence. Sosei's primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide. For more information about Sosei, please visit www.sosei.com.

  • 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
    成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
    ・・・
    ※大日本住友製薬第1四半期決算説明会:北米COPD新製品群、本年10月に発売予定のシーブリもあわせ、売上拡大に注力。(7/28up)
    ※Pluristem: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018." (Change, 9/17up)
    ※ClinicalTrials.gov: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9." (9/18up)
    ※MRC LMB: Brochure "Impact: Heptares." (9/19update) ※LMB PhD Programme: "Cryo-EM of GPCRs." Applications now open. (9/22)
    ※MiNA: MiNA Research Team at OTS2017. "MTL-CEBPA, encouraging early clinical data in a Phase 1 trial in HCC."(9/22)
    ※日本特許:ムスカリンM1受容体作動薬としての二環式アザ化合物 (9/27公開)
    ※Protein Data Bank: A2A Adenosine Receptor Structure (LeadXpro and Heptares):5NLX, 5NM2. (9/27 Released)
    ※Heptares Corporate Overview 2017. (9/27update) ※Heptares_HP_Pipeline: Muscarinic M1 Status. (9/28Change)
    ・HTL009936/HTL0018318: first-in-class oral agents in Phase 1 clinical studies. "Planning underway for studies in AD patients"
    ・Wave 1 Partnered Pipeline: M1, Progression 2017-2019: "Start of Phase 2 POC trial in AD patients", "AD PoC results emerging"
    ・Wave 2 Proprietary Pipeline: "Multiple Candidates Entering Clinic from H2 2017", "mGlu5: 2017 Phase 1 SAD/MAD and PET receptor occupancy"
    ※米国特許出願:4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGlu5 Modulators. (9/28公開)
    ※mGlu International Meeting: "Structure Based Drug Design Applied to the mGlu5 Receptor." Fiona Marshall. (10/2)
    ※Fiona Marshall: So delighted that Heptares founder Richard Henderson has won the Nobel Prize. "Uses of Cryo-EM Just Beginning." (10/4)
    ※Heptares: We're delighted to hear that Heptares co-founder Richard Henderson is a recipient of this year's Nobel Prize in Chemistry.(10/4)
    ・・・
    ※Novartis Q3 2017 Earnings Conference Call: (10/24)
    ※大日本住友製薬 2018年3月期第2四半期決算発表: (10/30)
    ※Pfizer Quarterly Corporate Performance Q3 2017: (10/31)
    ※Allergan Q3 2017 Earnings Conference Call: (11/1) 10/2up
    ※Teva Q3 2017 Earnings Conference Call: (11/2)
    ・・・
    ※SOSEIの成長相場の動向:
    ・Bloomberg:創薬ベンチャーのそーせいは買収を通じて業容を拡大し、株価は過去2年間で約300%上昇(2015/3/17終値2972→2017/3/17終値10750)。
    2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22※最安値1854、2014/9/8最高値6000: PfizerUK)※[成長回収期の入口]ステージへ
    2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章]ステージへ
    2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24※安値3550) (2015/10/29※終値3885:Utibron・Seebri米国承認)※[次なる飛躍]ステージへ
    2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(201511/30終値6060:Pfizer、12/1安値7060)※[上抜け圏]へ・(4/6終値14180:Allergan)※[強気相場]
    2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/5/9最高値26180、6/24安値12960)※[強気相場解除]※[時間軸での調整局面]へ
    2016/12/30 (終値13450) 売残高__300 買残高 2920000 ・(2016/12/8安値12470、1/24安値12910、2/13安値12400)※[時間軸調整は順調に推移]
    2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380) ※[仕掛け、振るい場・拾い場]へ
    2017/_6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960)※[調整終盤での動意待ち]
    2017/_8/25 (終値_9020) 売残高_6400 買残高 2018100(+154400) ・(7/31安値11280、8/10安値10280、8/24安値8860)
    2017/_9/_1 (終値_9710) 売残高_2400 買残高 2048100(_+30000) ・(8/29安値8860)
    2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800(_-10300) ・(9/6※最安値8590)
    2017/_9/15 (終値_8850) 売残高____0 買残高 2002400(_-35400) ・(9/11安値8630)
    2017/_9/22 (終値_9200) 売残高__100 買残高 2021100(_+18700) ・(9/19,20安値8820)
    2017/_9/29 (終値_9500) 売残高_1000 買残高 1961700(_-59400)※10/3up ・(9/26安値8960)※[振るい・拾い場も順調]
    2017/10/_2 (終値_9400) 5日線乖離(+2.02%) 25日線乖離(+3.99%) 75日乖離(-10.91%) 200日線乖離(-18.96%) (安値9360)
    2017/10/_3 (終値_9310) 5日線乖離(+0.28%) 25日線乖離(+2.91%) 75日乖離(-11.54%) 200日線乖離(-19.59%) (安値9260)
    2017/10/_4 (終値_9120) 5日線乖離(-1.81%) 25日線乖離(+0.70%) 75日乖離(-13.12%) 200日線乖離(-21.07%) (安値9090)

    上抜け圏にて、強気相場解除後の時間軸調整は順調に推移。笑。
    ※SOSEI Technical Analysis Charts:
    (ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=120&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us)

    時間軸調整の終盤、今回も予定通りに推移してますね。笑。

    次なる展開・進捗が楽しみですね。笑。

  • ※Nobel chemistry prize for developers of “Cool Microscopy”. Technique generates 3D images used for drugs to treat Zika and other diseases.
    30 Minutes Ago

    The Nobel chemistry prize has been awarded to three scientists who developed what their citation calls “cool microscopy that revolutionises biochemistry”.

    Jacques Dubochet of Switzerland, Joachim Frank, a German-born American,
    and Richard Henderson of the UK share the SKr 9m ($1.1m) award for discoveries from the 1970s to 1990s that led to “Cryo-Electron Microscopy”.

    Cry-EM, as the technique is known, enables researchers to see individual atoms within biological molecules.
    Last year, for example, it was used to generate 3D images of the Zika virus.

    Professor Dubochet, 75, is at the University of Lausanne and Professor Frank, 77, at Columbia University, New York.
    Dr Henderson, 72, a Scot working at the MRC Laboratory of Molecular Biology in Cambridge, “is the 15th Nobel laureate from that lab - quite an achievement,” said Göran Hansson,
    secretary-general of the Royal Swedish Academy of Sciences.

    Speaking by phone to the Nobel press conference in Stockholm, Prof Frank said he was “speechless” when Mr Hansson woke him with news of the award:
    “I thought the chance of winning a Nobel Prize was minuscule because there are so many innovations and discoveries happening.”
    But Prof Frank added that cryo-EM “is about to transform structural biology”.

    That sentiment was shared by scientists using cryo-EM who celebrated the Nobel award.
    For example John Hardy, neuroscience professor at University College London,
    said the 3D structure of the enzyme producing deadly amyloid protein in Alzheimer’s disease was determined last year using cryo-EM.

    “Knowing this structure opens up the possibility of rational drug design in this area,” said Prof Hardy, “and as a biologist I can say that the pictures are beautiful.”

    Electron microscopy, originally developed in the 1930s,
    gives higher resolution images than traditional optical microscopes but it was not suitable for imaging biological material which could not survive powerful electron beams.
    Cryo-EM, however, freezes biomolecules in mid-movement without destroying them.

    The three laureates, working separately but keeping in contact with each other, made distinctive contributions.
    Prof Dubochet pioneered the process of vitrification - instantly encasing cells and molecules in ice - which froze them in their living shape.

    Dr Henderson discovered how to detect individual electrons in an electron microscope, making it possible for the first time to image proteins on an atomic scale.
    Prof Frank developed the necessary image processing technology.

    The pharmaceutical industry is now using cryo-EM.
    Last year Heptares, a biotech company co-founded by Dr Henderson,
    set up the Cambridge-Pharmaceutical Cryo-EM Consortium with four drug companies, a microscope manufacturer and two academic labs.
    They will use the technique for drug discovery and design.

  • ※MRC LMB: Richard Henderson wins 2017 Nobel Prize for Chemistry. (10/4)

    Richard HendersonRichard Henderson from the LMB’s Structural Studies Division has been awarded the 2017 Nobel Prize for Chemistry.
    Richard shares the honour jointly with Jacques Dubochet and Joachim Frank “for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution”.

    Speaking after today’s announcement, Richard responded “I am delighted for everybody in the field that the Nobel Prize for Chemistry has been awarded to acknowledge the success of cryo-EM.
    I am particularly pleased that Jacques Dubochet has been recognised as the key person who kick-started the field in the early 1980s with his method of rapid freezing to make a specimen of amorphous ice, a crucial advance.”

    Richard was born and educated in Scotland.
    Following a PhD in Cambridge Richard worked at Yale University before returning to the LMB where he has been working since 1973 on using electron microscopy to solve complex membrane protein structures.
    Together with Nigel Unwin he successfully determined the first structure of 2-D crystals of the membrane protein bacteriorhodopsin using electron microscopy in 1975.
    Work over Richard’s career has helped to advance the technique of electron microscopy, which bombards proteins or other large biological molecules with electrons rather than X-rays, so that the atomic structure of proteins can be determined.
    This has allowed us to see the structure of large, flexible and complex proteins, which have been impossible to analyse by traditional X-ray crystallography techniques.

    In the 1990s, Richard realised that it would be theoretically possible to extract enough signal from randomly dispersed molecules using electron microscopy to obtain their detailed atomic structures.
    This insight and Richard’s drive and determination over the next two decades led to the development of better detectors for electron microscopes and better software to analyse the images.
    This revolutionised the technique of electron cryomicroscopy (cryoEM), which involves flash-cooling molecules in a thin layer of aqueous solution before imaging them,
    a crucial method invented by Jacques Dubochet and his colleagues in the early 1980s. Computational processing the images is a key step, to which Joachim Frank made major early contributions.

    In the last few years there has been a quantum step forward in these imaging techniques, due to better microscopes, better electron detectors and better computer programs for calculating the structure from the images.
    These improvements are now allowing atomic structure determinations of many protein and other macromolecular assemblies that were previously very difficult or impossible to obtain.
    The new structures provide important insights into the biological function of the assemblies and, by catalysing the subsequent development of new diagnostic or therapeutic tools, should help to improve the health and wealth of the country.

    Richard has been presented with many awards for his work, and was recently awarded the Gjonnes Medal in electron crystallography by the International Union of Crystallography.
    He is a Fellow of the Royal Society and the Academy of Medical Sciences, and was Director of the LMB from 1996-2006.

    Hugh Pelham, LMB Director, congratulated Richard on his spectacular achievements: “My warmest congratulations to Richard Henderson as well as Jacques Dubochet and Joachim Frank.
    This is a fantastic recognition of very many years of work developing this technology, which is already helping to solve key problems related to human health. It is incredible what can now be done.
    The impact will be profound and I am proud that the MRC Laboratory of Molecular Biology has played such a central role in this.”

    The work of LMB scientists has previously been recognised by the award of 10 Nobel prizes: 7 in the field of chemistry and 3 for physiology or medicine.

  • ※MRC LMB: Huge congratulations to Richard Henderson of MRC_LMB, Jacques Dubochet and Joachim Frank for their NobelPrize in Chemistry! (10/4)
    MRC LMB_HP:
    The LMB is delighted to announce the awarding of the 2017 Nobel Prize in Chemistry to the LMB’s Richard Henderson, jointly with Jacques Dubochet and Joachim Frank “for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution”. More to follow soon.


    ※We are now accepting applications for our PhD programme. (9/22up)
    Projects:
    The PhD projects available for studies leading to a University of Cambridge PhD degree commencing 1 October 2018 are listed below.
    ・Chris Tate: "Cryo-EM of GPCRs."

    Chris Tate: "Structural StudiesStructure of activated states of G protein-coupled receptors by Electron Cryo-Microscopy."

    The structures of G protein-coupled receptors in multiple different conformations are necessary to understand how agonists activate the receptor to facilitate G protein coupling.
    In addition, structures are also required bound to arrestins to understand the molecular mechanism of biased agonism.
    We have developed a thermostabilisation technology that has allowed us to determine the structures of multiple different GPCRs bound to inverse agonists, partial agonists, biased agonists and full agonists.
    Recently, we also developed a thermostabilised G protein that has allowed us to determine the structure of the activated state of the adenosine A2A receptor.
    We wish to build on these successes and to utilise the developments in electron cryo-microscopy to determine structures of GPCRs bound to stabilised heterotrimeric G proteins and arrestin by single particle imaging.

    The successful candidate will be expected to learn all the steps involved in the overexpression, purification and preparation of cryo-EM samples of a GPCR
    and to determine one or more structures using the Titan Krios equipped with state of the art detectors.


    ※Brochure - MRC LMB. (9/19 update)
    Impact:
    The LMB has an enviable track record in promoting the application of its research findings.
    Researchers at the LMB benefit from the Laboratory’s long experience in this field, and from being able to access expert advice on how best to exploit their discoveries
    - whether by the licensing of patents, collaborations with existing companies or by founding new spin-off companies.
    ・・・
    Other notable contributions include the development of laser-scanning confocal microscopes
    and the more recent spin-off, Heptares Therapeutics, exploiting structural analysis of G-protein-coupled receptors for drug design.
    The location of AstraZeneca adjacent to the Laboratory has led to a joint collaboration fund to foster interactions,
    and other biomedical companies including Pfizer, GlaxoSmithKline, Heptares and Eli Lilly also fund work at the LMB.
    Methods to determine atomic structures of macromolecules by electron microscopy, developed at the LMB, are being transferred to industry to further their own research and development.

    Impact: Heptares Therapeutics.
    In 2007 the LMB’s Richard Henderson and Chris Tate co-founded Heptares Therapeutics to exploit pioneering new technology to stabilise G-protein-coupled receptors (GPCRs).

    As Chris comments:
    'Understanding the structure of GPCRs at a molecular level is important in designing new and more effective drugs to combat many human illnesses.

    Heptares’ StaR (Stabilised Receptor) technology platform allows us to apply contemporary drug discovery approaches to stabilised GPCRs
    - improving the chances of finding drugs to previously intractable targets and enabling the development of safer and more selective therapeutic agents.'

    Heptares is using this technology to work on its own and with partners to discover new medicines to target key diseases such as Alzheimer’s, schizophrenia, type 2 diabetes, cancers and HIV.


    ※Heptares:will be relocating to the Cambridge area in "July 2018". (9/6up)

  • ※Nobel prize in chemistry awarded for method to visualise biomolecules.
    Jacques Dubochet, Joachim Frank and Richard Henderson receive £825,000 prize for developing method for generating 3D images of life-building structures
    4 October 2017

    The Nobel prize in chemistry has been awarded to three scientists for developing a technique to produce images of the molecules of life frozen in time.

    Jacques Dubochet, Joachim Frank and Richard Henderson will receive equal shares of the 9m Swedish kronor (£825,000) prize, which was announced by the Royal Swedish Academy of Sciences in Stockholm on Wednesday.

    The technique they developed, called cryo-electron microscopy, has allowed the structure of biomolecules to be studied in high-resolution for the first time, an advance that revolutionised the field of biochemistry.

    Before the breakthrough, electron microscopes were only suitable for imaging dead matter, because the powerful electron beam destroyed biological material.
    Henderson, a Scottish scientist and professor at the MRC Laboratory of Molecular Biology, succeeded in using one of these microscopes to generate the first three-dimensional image of a protein at atomic resolution.

    Joachim Frank, a German-born professor at Colombia University in New York, made the technology more generally applicable.
    Dubochet, who is Swiss and an honorary professor at the University of Lausanne, refined a vitrification technique that allowed biomolecules to be rapidly frozen while retaining their natural shape.

    The resultant imaging technique has allowed scientists to explore the architecture of everything from the proteins that cause antibiotic resistance to the surface of the Zika virus.
    And by capturing snapshots of the same system at different time-points, scientists can stitch together jittery film sequences of biological processes as they unfold.

    This has paved the way for both new basic insights into life’s chemistry and for the development of pharmaceuticals.

    Last year’s prize went to three European chemists for developing “nano-machines”, an advance that paved the way for the world’s first smart materials.

  • ※Press Release: The Nobel Prize in Chemistry 2017
    4 October 2017

    The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2017 to

    Jacques Dubochet
    University of Lausanne, Switzerland

    Joachim Frank
    Columbia University, New York, USA

    and

    Richard Henderson
    MRC Laboratory of Molecular Biology, Cambridge, UK

    "for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution"


    Cool microscope technology revolutionises biochemistry:

    We may soon have detailed images of life’s complex machineries in atomic resolution.
    The Nobel Prize in Chemistry 2017 is awarded to Jacques Dubochet, Joachim Frank and Richard Henderson for the development of cryo-electron microscopy, which both simplifies and improves the imaging of biomolecules.
    This method has moved biochemistry into a new era.

    A picture is a key to understanding. Scientific breakthroughs often build upon the successful visualisation of objects invisible to the human eye.
    However, biochemical maps have long been filled with blank spaces because the available technology has had difficulty generating images of much of life’s molecular machinery.
    Cryo-electron microscopy changes all of this.
    Researchers can now freeze biomolecules mid-movement and visualise processes they have never previously seen,
    which is decisive for both the basic understanding of life’s chemistry and for the development of pharmaceuticals.

    Electron microscopes were long believed to only be suitable for imaging dead matter, because the powerful electron beam destroys biological material.
    But in 1990, Richard Henderson succeeded in using an electron microscope to generate a three-dimensional image of a protein at atomic resolution.
    This breakthrough proved the technology’s potential.

    Joachim Frank made the technology generally applicable.
    Between 1975 and 1986 he developed an image processing method in which the electron microscope’s fuzzy twodimensional images are analysed and merged to reveal a sharp three-dimensional structure.

    Jacques Dubochet added water to electron microscopy. Liquid water evaporates in the electron microscope’s vacuum, which makes the biomolecules collapse.
    In the early 1980s, Dubochet succeeded in vitrifying water -
    he cooled water so rapidly that it solidified in its liquid form around a biological sample, allowing the biomolecules to retain their natural shape even in a vacuum.

    Following these discoveries, the electron microscope’s every nut and bolt have been optimised.
    The desired atomic resolution was reached in 2013, and researchers can now routinely produce three-dimensional structures of biomolecules.
    In the past few years, scientific literature has been filled with images of everything from proteins that cause antibiotic resistance, to the surface of the Zika virus.
    Biochemistry is now facing an explosive development and is all set for an exciting future.

  • ※Fiona Marshall 4 分前: So delighted that Heptares founder Richard Henderson has won the Nobel Prize. Well deserved. Uses of cryo-EM just beginning.

    Richard Henderson, born in Scotland, age 72. Programme Leader, MRC Laboratory of Molecular Biology, Cambridge, UK: ttp://www2.mrc-lmb.cam.ac.uk/groups/rh15/

  • 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
    成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
    ・・・
    ※大日本住友製薬第1四半期決算説明会:北米COPD新製品群、本年10月に発売予定のシーブリもあわせ、売上拡大に注力してまいります。(7/28up)
    ※Pluristem: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018." (Change, 9/17up)
    ※ClinicalTrials.gov: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9." (9/18up)
    ※MRC LMB: Brochure "Impact: Heptares." (9/19update) ※LMB PhD Programme: "Cryo-EM of GPCRs." Applications now open. (9/22)
    ※MiNA: MiNA Research Team at OTS2017. "MTL-CEBPA, encouraging early clinical data in a Phase 1 trial in HCC."(9/22)
    ※日本特許:ムスカリンM1受容体作動薬としての二環式アザ化合物 (9/27公開)
    ※Protein Data Bank: A2A Adenosine Receptor Structure (LeadXpro and Heptares):5NLX, 5NM2. (9/27 Released)
    ※Heptares Corporate Overview 2017. (9/27update) ※Heptares_HP_Pipeline: Muscarinic M1 Status. (9/28Change)
    ・HTL009936/HTL0018318: first-in-class oral agents in Phase 1 clinical studies. "Planning underway for studies in AD patients"
    ・Wave 1 Partnered Pipeline: M1, Progression 2017-2019: "Start of Phase 2 POC trial in AD patients", "AD PoC results emerging"
    ・Wave 2 Proprietary Pipeline: "Multiple Candidates Entering Clinic from H2 2017", "mGlu5: 2017 Phase 1 SAD/MAD and PET receptor occupancy"
    ※米国特許出願:4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGlu5 Modulators. (9/28公開)
    ※mGlu International Meeting: "Structure Based Drug Design Applied to the mGlu5 Receptor." Fiona Marshall. (10/2)
    ※Drug Discovery 2017: "Deciphering GPCR-ligand interactions through structural and biophysical investigations." Rob Cooke. (10/3)
    (Heptares Rob Cooke walks us through unexpected binding sites in GPCR. The Merck MK-0893 Story a GCGR Antagonist.)
    (Some targets w/ no druggable sites at all, others with multiple ones: PAR2 + its Astrazeneca AZ8838 Antagonist. Heptares)
    ・・・
    ※23rd Annual Pharmaceutical Pricing and Market Access: 11-12 October 2017, London, UK. (9/19up)
    ・Attending: Heptares Therapeutics.
    ※K4DD Scientific Meeting: 16-18 October 2017, Berlin, Germany. (9/21update)
    ・17 Oct, 17:30, "Building a complete picture: kinetics, thermodynamics and structural determination of stabilised G protein-coupled receptors" Elena Segala.
    ・・・
    ※Novartis Q3 2017 Earnings Conference Call: (10/24)
    ※大日本住友製薬 2018年3月期第2四半期決算発表: (10/30)
    ※Pfizer Quarterly Corporate Performance Q3 2017: (10/31)
    ※Allergan Q3 2017 Earnings Conference Call: (11/1) 10/2up
    ※Teva Q3 2017 Earnings Conference Call: (11/2)
    ・・・
    ※SOSEIの成長相場の動向:
    _3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380) ※[仕掛け、振るい場・拾い場]へ
    _6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960) ※[調整終盤での動意待ち]
    _8/10 (終値10410) 売残高_6100 買残高 1787400(_+20700) ・(7/31安値11280、8/10安値10280)
    _8/18 (終値_9580) 売残高18400 買残高 1862700(_+75300) ・(8/18安値9530)
    _8/25 (終値_9020) 売残高_6400 買残高 2018100(+154400) ・(8/24安値8860)
    _9/_1 (終値_9710) 売残高_2400 買残高 2048100(_+30000) ・(8/29安値8860)
    _9/_8 (終値_8700) 売残高_1900 買残高 2037800(_-10300) ・(9/6※最安値8590)
    _9/15 (終値_8850) 売残高____0 買残高 2002400(_-35400) ・(9/11安値8630)
    _9/22 (終値_9200) 売残高__100 買残高 2021100(_+18700) ・(9/19,20安値8820)
    _9/29 (終値_9500) 売残高_1000 買残高 1961700(_-59400)※10/3up ・(9/26安値8960) ※[振るい・拾い場も順調に推移]
    10/_2 (終値_9400) 5日線乖離(+2.02%) 25日線乖離(+3.99%) 75日乖離(-10.91%) 200日線乖離(-18.96%) (安値9360)
    10/_3 (終値_9310) 5日線乖離(+0.28%) 25日線乖離(+2.91%) 75日乖離(-11.54%) 200日線乖離(-19.59%) (安値9260)
    10/_4 (終値_9120) 5日線乖離(-1.81%) 25日線乖離(+0.70%) 75日乖離(-13.12%) 200日線乖離(-21.07%) (安値9090)

    上抜け圏にて、強気相場解除後の時間軸調整は順調に推移。笑。

    ※SOSEI Technical Analysis Charts (Day):
    (ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=DAY1&Duration=24&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us)

    時間軸調整の終盤、今回も予定通りに推移してますね。笑。

    次なる展開・進捗が楽しみですね。笑。

  • 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
    成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
    ・・・
    ※Pluristem: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018." (Change, 9/17up)
    ※ClinicalTrials.gov: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9." (9/18up)
    ※MRC LMB: Brochure "Impact: Heptares." (9/19update) ※LMB PhD Programme: "Cryo-EM of GPCRs." Applications now open. (9/22)
    ※MiNA: MiNA Research Team at OTS2017. "MTL-CEBPA, encouraging early clinical data in a Phase 1 trial in HCC."(9/22)
    ※日本特許:ムスカリンM1受容体作動薬としての二環式アザ化合物 (9/27公開)
    ※Protein Data Bank: A2A Adenosine Receptor Structure (LeadXpro and Heptares):5NLX, 5NM2. (9/27 Released)
    ※Heptares Corporate Overview 2017. (9/27update) ※Heptares_HP_Pipeline: Muscarinic M1 Status. (9/28Change)
    ・HTL009936/HTL0018318: first-in-class oral agents in Phase 1 clinical studies. "Planning underway for studies in AD patients"
    ・Wave 1 Partnered Pipeline: M1, Progression 2017-2019: "Start of Phase 2 POC trial in AD patients", "AD PoC results emerging"
    ・Wave 2 Proprietary Pipeline: "Multiple Candidates Entering Clinic from H2 2017", "mGlu5: 2017 Phase 1 SAD/MAD and PET receptor occupancy"
    ※米国特許出願:4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGlu5 Modulators. (9/28公開)
    ※mGlu International Meeting: "Structure Based Drug Design Applied to the mGlu5 Receptor." Fiona Marshall. (10/2)
    ※SOSEI:Financial Data 2017 (2013年3月期 ~ 2017年3月期 Consolidated Financial Data).(10/2)
    ・・・
    ※SOSEI Estimates Analysis 2018, 2019: Estimates Sales, Earnings: (Mean, High, Low, 1 Year Ago):
    ※SOSEI Earnings Forecast 2018 - 2022:
    ・・・
    ※Novartis Q3 2017 Earnings Conference Call: (10/24)
    ※大日本住友製薬 2018年3月期第2四半期決算発表: (10/30)
    ※Pfizer Quarterly Corporate Performance Q3 2017: (10/31)
    ※Allergan Q3 2017 Earnings Conference Call: (11/1) 10/2up
    ※Teva Q3 2017 Earnings Conference Call: (11/2)
    ・・・
    ※SOSEIの成長相場の動向:
    ・Bloomberg:創薬ベンチャーのそーせいは買収を通じて業容を拡大し、株価は過去2年間で約300%上昇(2015/3/17終値2972→2017/3/17終値10750)。
    2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22※最安値1854、2014/9/8最高値6000: PfizerUK)※[成長回収期の入口]ステージへ
    2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章]ステージへ
    2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24※安値3550) (2015/10/29※終値3885:Utibron・Seebri米国承認)※[次なる飛躍]ステージへ
    2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(201511/30終値6060:Pfizer、12/1安値7060)※[上抜け圏]へ・(4/6終値14180:Allergan)※[強気相場]
    2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/5/9最高値26180、6/24安値12960)※[強気相場解除]※[時間軸での調整局面]へ
    2016/12/30 (終値13450) 売残高__300 買残高 2920000 ・(2016/12/8安値12470、1/24安値12910、2/13安値12400)※[時間軸調整は順調に推移]
    2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380) ※[仕掛け、振るい場・拾い場]へ
    2017/_6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960)※[調整終盤での動意待ち]
    2017/_8/10 (終値10410) 売残高_6100 買残高 1787400(_+20700) ・(7/31安値11280、8/10安値10280)
    2017/_8/18 (終値_9580) 売残高18400 買残高 1862700(_+75300) ・(8/18安値9530)
    2017/_8/25 (終値_9020) 売残高_6400 買残高 2018100(+154400) ・(8/24安値8860)
    ・ドイツ銀行ロンドン支店大量保有報告書提出。報告義務発生日:8/31、保有割合:5.7%。(9/7)
    2017/_9/_1 (終値_9710) 売残高_2400 買残高 2048100(_+30000) ・(8/29安値8860)
    2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800(_-10300) ・(9/6※最安値8590)
    2017/_9/15 (終値_8850) 売残高____0 買残高 2002400(_-35400) ・(9/11安値8630)
    ・JPモルガン・アセット・マネジメント変更報告書提出。報告義務発生日:9/15、共同保有割合:7.39%、筆頭保有割合:5.19%。(9/25)
    ・五味大輔(個人)変更報告書を提出。報告義務発生日:9/21、保有割合は6.13%(1.05増加)。(9/26)
    2017/_9/22 (終値_9200) 売残高__100 買残高 2021100(_+18700) ・(9/19,20安値8820)
    2017/_9/29 (終値_9500) 売残高_1000 買残高 1961700(_-59400)※10/3up ・(9/26安値8960)※[振るい・拾い場も順調]
    2017/10/_2 (終値_9400) 5日線乖離(+2.02%) 25日線乖離(+3.99%) 75日乖離(-10.91%) 200日線乖離(-18.96%) (安値9360)
    2017/10/_3 (終値_9310) 5日線乖離(+0.28%) 25日線乖離(+2.91%) 75日乖離(-11.54%) 200日線乖離(-19.59%) (安値9260)

    上抜け圏にて、強気相場解除後の時間軸調整は順調に推移。笑。

    (ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=120&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us)

    時間軸調整の終盤、今回も予定通りに推移してますね。笑。

    次なる展開・進捗が楽しみですね。笑。

  • 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
    成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
    ・・・
    ※米国特許:Muscarinic Agonists. (9/12公開)
    ※Pluristem: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018." (Change, 9/17up)
    ※ClinicalTrials.gov: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9." (9/18up)
    ※SOSEI:新インベスターリレーションズ/コーポレートコミュニケーション部長並びに当グループ経理財務部長任命。(9/19)
    ※MRC LMB: Brochure "Impact: Heptares." (9/19update) ※LMB PhD Programme: "Cryo-EM of GPCRs." Applications now open. (9/22)
    ※JITSUBO:当社技術に関連する論文を追加しました。(9/22)
    ※MiNA: MiNA Research Team at OTS2017. "MTL-CEBPA, encouraging early clinical data in a Phase 1 trial in HCC."(9/22)
    ※日本特許:ムスカリンM1受容体作動薬としての二環式アザ化合物 (9/27公開)
    ※Protein Data Bank: A2A Adenosine Receptor Structure (LeadXpro and Heptares):5NLX, 5NM2. (9/27 Released)
    ※Heptares Corporate Overview 2017. (9/27update) ※Heptares_HP_Pipeline: Muscarinic M1 Status. (9/28Change)
    ※米国特許出願:4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGlu5 Modulators. (9/28公開)
    ※mGlu International Meeting: "Structure Based Drug Design Applied to the mGlu5 Receptor." Fiona Marshall. (10/2)
    ※SOSEI:Financial Data 2017 (2013年3月期 ~ 2017年3月期 Consolidated Financial Data).(10/2)
    ・・・
    ※Drug Discovery 2017: "Deciphering GPCR-ligand interactions through structural and biophysical investigations." Robert Cooke. (Today 15:45)
    ・・・
    ※SOSEIの成長相場の動向:上抜け圏にて、強気相場解除後の時間軸調整は順調に推移。笑。
    _8/10 (終値10410) 売残高_6100 買残高 1787400(_+20700) ・(8/10安値10280)
    _8/18 (終値_9580) 売残高18400 買残高 1862700(_+75300) ・(8/18安値9530)
    _8/25 (終値_9020) 売残高_6400 買残高 2018100(+154400) ・(8/24安値8860)
    _9/_1 (終値_9710) 売残高_2400 買残高 2048100(_+30000) ・(8/29安値8860)
    _9/_8 (終値_8700) 売残高_1900 買残高 2037800(_-10300) ・(9/6※最安値8590)
    _9/15 (終値_8850) 売残高____0 買残高 2002400(_-35400) ・(9/11安値8630)
    _9/22 (終値_9200) 売残高__100 買残高 2021100(_+18700) ・(9/19,20安値8820)
    _9/29 (終値_9500) 売残高_1000 買残高 1961700(_-59400)※update ・(9/26安値8960)
    10/_2 (終値_9400) 5日線乖離(+2.02%) 25日線乖離(+3.99%) 75日乖離(-10.91%) 200日線乖離(-18.96%) (安値9360)
    10/_3 (終値_9310) 5日線乖離(+0.28%) 25日線乖離(+2.91%) 75日乖離(-11.54%) 200日線乖離(-19.59%) (安値9260)

    時間軸調整の終盤、振るい・拾い場も順調に推移。笑。

    (ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=120&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us)

    今回も予定通りに推移してますね。笑。

    次なる展開・進捗が楽しみですね。笑。

  • ・・・
    ※Novartis Q3 2017 Earnings Conference Call: (10/24)
    ※大日本住友製薬 2018年3月期第2四半期決算発表: (10/30)
    ※Pfizer Quarterly Corporate Performance Q3 2017: (10/31)
    ※Allergan Q3 2017 Earnings Conference Call: (11/1) 10/2up
    ※Teva Q3 2017 Earnings Conference Call: (11/2)
    ※MorphoSys Publication of Q3 Interim Statement 2017: (11/7)
    ※明治ホールディングス 平成30年3月期 第2四半期決算発表: (11/8)
    ※AstraZeneca Year-to-date and Q3 2017 Results: (11/9)
    ※あすか製薬 平成30年3月期第2四半期決算発表: (11月上旬)
    ※ペプチドリーム 平成30年6月期第1四半期決算発表: (11月上旬)
    ※SOSEI 平成30年3月期第2四半期決算発表: (11月中旬)
    ・・・
    ※SOSEIの成長相場の動向:
    ・Bloomberg:創薬ベンチャーのそーせいは買収を通じて業容を拡大し、株価は過去2年間で約300%上昇(2015/3/17終値2972→2017/3/17終値10750)。
    2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22※最安値1854、2014/9/8最高値6000: PfizerUK)※[成長回収期の入口]ステージへ
    2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章]ステージへ
    2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24※安値3550) (2015/10/29※終値3885:Utibron・Seebri米国承認)※[次なる飛躍]ステージへ
    2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(201511/30終値6060:Pfizer、12/1安値7060)※[上抜け圏]へ・(4/6終値14180:Allergan)※[強気相場]
    2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/5/9最高値26180、6/24安値12960)※[強気相場解除]※[時間軸での調整局面]へ
    2016/12/30 (終値13450) 売残高__300 買残高 2920000 ・(2016/12/8安値12470、1/24安値12910、2/13安値12400)※[時間軸調整は順調に推移]
    2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380) ※[仕掛け、振るい場・拾い場]へ
    2017/_6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960)※[調整終盤での動意待ち]
    2017/_9/22 (終値_9200) 売残高__100 買残高 2021100 ・(7/31安値11280、8/24,29安値8860、9/6最安値8590)※[振るい・拾い場も順調に推移]
    2017/_9/29 (終値_9500) 5日線乖離(+3.80%) 25日線乖離(+5.27%) 75日乖離(-10.19%) 200日線乖離(-18.24%) (安値9090) ・(9/26安値8960)
    2017/10/_2 (終値_9400) 5日線乖離(+2.02%) 25日線乖離(+3.99%) 75日乖離(-10.91%) 200日線乖離(-18.96%) (安値9360)

    ※SOSEI Technical Analysis Charts: 上抜け圏にて、強気相場解除後の時間軸調整は順調に推移。笑。
    (ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=805&Height=650&Cycle=WEEK1&Duration=60&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us)
    時間軸調整の終盤、今回も予定通りに推移してますね。笑。

    R&D等の拡充・進捗や中長期成長戦略も着実に進み、
    次なる展開・進捗が楽しみですね。笑。

本文はここまでです このページの先頭へ